DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-164/S-057

Aventis Pharmaceuticals, Inc.
Attention: Steve Caffé, M.D.
Head, U.S. Regulatory Affairs
200 Crossing Blvd
Bridgewater, NJ 08807

Dear Dr. Caffé:

Please refer to your supplemental new drug application dated November 17, 2003, received November 18, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lovenox® (fondaparinux sodium, injection).

We acknowledge receipt of your submission dated May 5, 2004.

This "Changes Being Effected" supplemental new drug application provides for changes in the **ADVERSE REACTIONS** section, *Ongoing Safety Surveillance* subsection of the Lovenox package insert (PI) to include rare cases of hypersensitivity cutaneous vasculitis.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text and with the revisions listed below.

1. Incorporate the revisions to the PI approved in S-048 on December 18, 2003.

2. Delete the reference and associated superscript to "Riffitts, M., "Enoxaparin and Vasculitis" Reasoned Statement, by Global Pharmacovigilance, March 6, 2003.

The final printed labeling (FPL) must be identical, and include the revisions indicated, to the submitted labeling (package insert submitted November 17, 2003). These revisions are terms of the approval of this application.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-164/S-057." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Diane Moore, Regulatory Project Manager, at (301) 827-7476.

Sincerely,

{See appended electronic signature page}

Robert L. Justice, M.D., M.S.
Director
Division of Gastrointestinal & Coagulation Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Joyce Korvick
5/18/04 04:06:33 PM
for Dr. Robert Justice